



NDA 200533/S-018, S-019

**SUPPLEMENT APPROVAL**

Depo NF SUB, LLC  
C/O Collegium Pharmaceutical Inc.  
100 Technology Center Drive, Suite 300  
Stoughton, MA 02072

Attention: Liz Stuart, PharmD, RAC  
Director, Regulatory Affairs

Dear Dr. Stuart:

Please refer to the following Supplemental New Drug Applications (sNDAs) dated and received March 30, 2018, and June 28, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for NUCYNTA ER (tapentadol) Extended-Release Tablets.

We also refer to our letter dated September 28, 2017, notifying you that under section 505-1 of the FDCA, we have determined that your approved Extended-Release and Long-Acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) must be modified to ensure that training is made available to healthcare providers involved in the treatment and monitoring of patients with pain, and to implement the FDA Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain to ensure the benefits of the drugs outweigh the risks of adverse outcomes (addiction, unintentional overdose, and death) resulting from inappropriate prescribing, abuse, and misuse.

Finally, we refer to our letter dated June 1, 2018, notifying you, under section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for NUCYNTA ER. This information pertains to the addition of the REMS program details to product labeling for the class of opioid analgesics intended for use in the outpatient setting.

Supplement S-018 provides for the REMS modification required under section 505-1 of the FDCA, consistent with our September 28, 2017, letter.

Supplement S-019 provides for revisions to the labeling for NUCYNTA ER consistent with our June 1, 2018, Safety Labeling Change Notification letter.

## **APPROVAL & LABELING**

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

## **WAIVER OF HIGHLIGHTS SECTION**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

## **RISK EVALUATION AND MITIGATION STRATEGY (REMS)**

The REMS for Extended-Release and Long-Acting (ER/LA) opioid analgesics products, of which NUCYNTA ER is a member, was originally approved on July 9, 2012, and the most recent REMS modification was approved on May 26, 2017. The REMS consists of a Medication Guide, elements to assure safe use, and a timetable for submission of assessments of the REMS.

In order to ensure the benefits of certain opioid analgesics intended for use in the outpatient setting outweigh their risks of adverse outcomes (addiction, unintentional overdose, and death) resulting from inappropriate prescribing, abuse, and misuse, we determined that you were required to make the REMS modifications outlined in our REMS Modification letter dated September 28, 2017.

Your proposed modified REMS, submitted to Drug Master File (DMF) (b)(4) on March 26, 2018, amended and appended to this letter, is approved. The modified REMS consists of a Medication Guide, elements to assure safe use, and a timetable for submission of assessments of the REMS.

This REMS uses a shared system for the elements to assure safe use and the REMS assessments. This shared system, now known as the Opioid Analgesics REMS Program, includes the products listed on the FDA REMS website, available at <https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm>

Other products may be added in the future if additional NDAs or ANDAs are approved.

The revised REMS assessment plan must include, but is not limited to, the following:

1. REMS Outreach and Communication

- a. For each healthcare provider (e.g., prescriber, pharmacist) to be sent information regarding REMS-compliant accredited continuing education (CE), provide the date when the letters were sent; the number of letters electronically sent, received, undeliverable, and opened; and the number of letters mailed and undeliverable
- b. For each professional society, association, and licensing board to be sent information regarding REMS-compliant accredited CE, provide the number of letters electronically sent, received, undeliverable, and opened; and the number of letters mailed and undeliverable

2. REMS Implementation and Operations

- a. Status of grants
  - i. The status of the request for proposals for grants for REMS-compliant accredited CE including:
    1. Request for Application (RFA) issued: date and number of applications submitted in response to each RFA
    2. RFAs awarded: date, number, and name of grantee
    3. Date/timeframe next RFA to be issued

- ii. The status of the requests for proposals for any grants to CE Providers or other CE organizations with expertise in assessing CE outcomes who agree to conduct evaluations of health care providers who have taken REMS-compliant accredited CE funded under this REMS.
- b. Grant review committee
- i. Individuals from the REMS Program Companies (RPC) reviewing grants will include the following clinical licensures: pharmacists, nurses, physicians. Additionally there will be involvement by individuals with regulatory and pharmacovigilance experience. The job title, licensure and professional degree of individuals will be provided for each grant review cycle.
  - ii. Include any external members (non RPC) involved in the grant review, including those from the broad-based CE community. Provide the job title, licensure and professional degree of the individual for each grant review cycle.
- c. For CE programs awarded during the assessment period:
- i. Description of each grantee and projected number of completers
  - ii. For the first assessment, the date the first program based upon the FDA Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain (“FDA Blueprint”), became available
  - iii. Description of CE program:
    - 1. Level of outcome the activity<sup>1</sup> is designed to impact
    - 2. CE format (live, webinar, etc.)
    - 3. Duration of activity for live or webinar activities
    - 4. Average duration to complete for internet/enduring activities
    - 5. Education methods and tools (case-based, multimedia, didactic, interactive, adaptive, etc.)<sup>2,3</sup>
  - iv. All reports submitted to the RPC by CE grantees during the assessment period.

---

<sup>1</sup> Stevenson R, Moore DE. Ascent to the Summit of the CME Pyramid. *JAMA* 2018;319(6):543-544

<sup>2</sup> Cervero R, Gaines J. The Impact of CME on Physician Performance and Patient Health Outcomes: An Updated Synthesis of Systematic Reviews *J Contin Educ Health Prof* 2015;35(2):131-138

<sup>3</sup> Agency for Research Health and Quality. (2007). *Effectiveness of Continuing Medical Education*. Retrieved May 9, 2018, from <https://archive.ahrq.gov/downloads/pub/evidence/pdf/cme/cme.pdf>

- d. Number of participants and completers during the assessment period; provide description of learners by standard learner category data<sup>4</sup>.
- e. Independent Audit: The results of independent audits of the CE. Audits must be conducted on a random sample of at least 10% of the REMS-compliant accredited CE funded under the Opioid Analgesic REMS and must include/evaluate:
  - i. a description of the organization(s) conducting the audit(s)
  - ii. whether the content of the REMS-compliant accredited CE covers all elements of the FDA Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain (“FDA Blueprint”) approved as part of the REMS;
  - iii. whether the integrated or post-course knowledge assessment measures knowledge of all sections of the FDA Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain (“FDA Blueprint”); and
  - iv. whether the REMS-compliant accredited CE was conducted in accordance with the Accreditation Council for Continuing Medication Education (ACCME) standards for CE or appropriate standards for accreditation bodies
- f. Concurrent Educational interventions
  - i. For the year prior to the assessment period through the assessment period, provide an evaluation of the overall pain/opioid CE landscape including but not limited to:
    - 1. States requiring prescribers, pharmacists, or nurses to complete opioid or pain management continuing education for licensing/renewal of licensing:
      - a. enumeration of these states and their requirements. for continuing education on either pain or safe opioid use,
      - b. estimates of annual licensed prescribers in those states
      - c. which, if any, opioid analgesic or ER/LA Opioid Analgesic REMS CE were permissible in which states, for prescribers to meet requirements

---

<sup>4</sup> Standard Continuing Education (CE) learner data to be captured by all CE Providers for Opioid Analgesic REMS includes geographic location (state of primary practice), DEA prescriber status (individual registration or institutional authorization), profession, practice area, and length of time in practice.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.